Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody

被引：40

作者：

Fujita, Kohei ^{[1
]}

Yamamoto, Yuki ^{[1
,2
]}

Kanai, Osamu ^{[1
]}

Okamura, Misato ^{[1
]}

Hashimoto, Masayuki ^{[3
]}

Nakatani, Koichi ^{[1
]}

Sawai, Satoru ^{[3
]}

Mio, Tadashi ^{[1
]}

机构：

[1] Natl Hosp Org Kyoto Med Ctr, Ctr Resp Dis, Div Resp Med, Kyoto, Japan

[2] Kyoto Univ, Grad Sch Med, Dept Drug Discovery Lung Dis, Kyoto, Japan

[3] Natl Hosp Org Kyoto Med Ctr, Ctr Resp Dis, Div Thorac Surg, Kyoto, Japan

来源：

THORACIC CANCER | 2020年 / 11卷 / 01期

关键词：

Anti-PD-1; anti-PD-L1; immune checkpoint inhibitors; lung cancer; retreatment; DOCETAXEL; NIVOLUMAB;

D O I：

10.1111/1759-7714.13241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background This study evaluated the efficacy and safety of retreatment with anti-programmed death 1 (anti-PD-1) antibodies in patients with advanced non-small cell lung cancer (NSCLC) after prior treatment with anti-programmed death-ligand 1 (anti-PD-L1) antibodies. Methods Data (N = 15) on patients' characteristics, number of cycles, regimens, their best response and immune-related adverse events (irAEs) were recorded retrospectively. Results NSCLC was initially treated with anti-PD-L1 antibody atezolizumab (N = 14) or durvalumab (N = 1). No patients had a high (>= 50%) tumor expression of PD-L1. The median cycles for atezolizumab were five (range 1-15), and median progression-free survival was 2.8 and 6.0 months for atezolizumab and durvalumab, respectively. Five (33.3%) and nine (60.0%) patients showed stable and progressive disease as their best response, respectively. No differences in irAEs between anti-PD-L1 and anti-PD-1 antibodies occurred. Conclusion Patients treated with anti-PD-L1 antibodies for NSCLC received limited benefits from retreatment with anti-PD-1 antibodies.

引用

页码：15 / 18

页数：4

共 13 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma [J].

Blasig, Hanna ;

Bender, Carolin ;

Hassel, Jessica C. ;

Eigentler, Thomas K. ;

Sachse, Michael M. ;

Hiernickel, Julia ;

Koop, Anika ;

Satzger, Imke ;

Gutzmer, Ralf .

MELANOMA RESEARCH, 2017, 27 (04) :321-325

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies [J].

Fujita, Kohei ;

Uchida, Naohiro ;

Yamamoto, Yuki ;

Kanai, Osamu ;

Okamura, Misato ;

Nakatani, Koichi ;

Sawai, Satoru ;

Mio, Tadashi .

ANTICANCER RESEARCH, 2019, 39 (07) :3917-3921

[6] Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases [J].

Fujita, Kohei ;

Uchida, Naohiro ;

Kanai, Osamu ;

Okamura, Misato ;

Nakatani, Koichi ;

Mio, Tadashi .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) :1105-1109

[7] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[8]

Niki Maiko, 2018, Oncotarget, V9, P32298, DOI 10.18632/oncotarget.25949

[9] Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab [J].

Nomura, Motoo ;

Otsuka, Atsushi ;

Kondo, Tomohiro ;

Nagai, Hiroki ;

Nonomura, Yumi ;

Kaku, Yo ;

Matsumoto, Shigemi ;

Muto, Manabu .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (05) :999-1004

[10] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].

Rittmeyer, Achim ;

Barlesi, Fabrice ;

Waterkamp, Daniel ;

Park, Keunchil ;

Ciardiello, Fortunato ;

von Pawel, Joachim ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Kowalski, Dariusz M. ;

Dols, Manuel Cobo ;

Cortinovis, Diego L. ;

Leach, Joseph ;

Polikoff, Jonathan ;

Barrios, Carlos ;

Kabbinavar, Fairooz ;

Frontera, Osvaldo Aren ;

De Marinis, Filippo ;

Turna, Hande ;

Lee, Jong-Seok ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

He, Pei ;

Chen, Daniel S. ;

Sandler, Alan ;

Gandara, David R. .

LANCET, 2017, 389 (10066) :255-265

← 1 2 →